1826843-81-5
中文名稱
Trastuzumab Deruxtecan
英文名稱
Trastuzumab Deruxtecan
CAS
1826843-81-5
更新日期
2024/10/28 23:00:50
Trastuzumab Deruxtecan價格(試劑級)
| 報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
| 2024/08/19 | HY-138298A | Trastuzumab Deruxtecan Trastuzumab deruxtecan | 1826843-81-5 | 1 mg | 6400元 |
| 2024/08/19 | HY-138298 | Trastuzumab Deruxtecan Trastuzumab deruxtecan | 1826843-81-5 | 1mg(10mg/mL * 100μL in Aqueous solution) | 6400元 |
| 2023/10/26 | HY-138298 | Trastuzumab Deruxtecan Trastuzumab deruxtecan | 1826843-81-5 | 5mg(10mg/mL * 500μL in Aqueous solution) | 20000元 |
常見問題列表
生物活性
Trastuzumab deruxtecan (DS-8201a) 是一種抗人表皮生長因子受體 2 (HER2) 抗體-藥物偶聯(lián)物 (ADC)。 Trastuzumab deruxtecan 由人源化抗 HER2 抗體，酶促裂解的肽接頭和拓?fù)洚悩?gòu)酶 I 抑制劑組成。Trastuzumab deruxtecan 可用于 HER2 陽性乳腺癌和胃癌的研究。體外研究
Trastuzumab deruxtecan (1 pM-10 nM; 5 days) inhibits the growth of HER2‐positive KPL‐4 cells, with an IC
50
of 109.7 pM.
Trastuzumab deruxtecan (10 nM; 5 days) shows bystander killing effects in HER2‐negative MDA‐MB‐468 cells.
Cell Viability Assay
| Cell Line: | KPL‐4 and MDA‐MB‐468 cells |
| Concentration: | 1, 10, 100, 1000, 10000 pM |
| Incubation Time: | 5 days |
| Result: | Killed both HER2‐positive KPL‐4 cells and HER2‐negative MDA‐MB‐468 cells. |
體內(nèi)研究
Trastuzumab deruxtecan (3 mg/kg; a single i.v.) shows antitumor activity against not only HER2‐positive tumors but also HER2‐negative tumors under the co‐inoculated condition.
Trastuzumab deruxtecan (10 mg/kg; i.v. on days 0 and 7) inhibits the tumor growth in in EMT6-hHER2 syngeneic mouse model.
| Animal Model: | Female BALB/c nude mice injected with NCI‐N87 and MDA‐MB‐468‐Luc cells |
| Dosage: | 3 mg/kg |
| Administration: | A single i.v. |
| Result: | Almost all of the HER2‐positive and HER‐negative cells disappeared and there were little or no cancer cells remaining in the tumors. |